These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33686452)

  • 1. A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.
    Azaro A; Massard C; Tap WD; Cassier PA; Merchan J; Italiano A; Anderson B; Yuen E; Yu D; Oakley G; Benhadji KA; Pant S
    Invest New Drugs; 2021 Aug; 39(4):1089-1098. PubMed ID: 33686452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors.
    Massard C; Cassier PA; Azaro A; Anderson B; Yuen E; Yu D; Oakley G; Benhadji KA; Pant S
    Cancer Chemother Pharmacol; 2022 Oct; 90(4):335-344. PubMed ID: 36030462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors.
    Doi T; Tajimi M; Mori J; Asou H; Inoue K; Benhadji KA; Naito Y
    Invest New Drugs; 2021 Apr; 39(2):469-476. PubMed ID: 32939607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer.
    Azaro A; Baldini C; Rodon J; Soria JC; Yuen E; Lithio A; Oakley G; Benhadji KA; Massard C
    Invest New Drugs; 2021 Feb; 39(1):193-201. PubMed ID: 32915419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer.
    Massard C; Azaro A; Soria JC; Lassen U; Le Tourneau C; Sarker D; Smith C; Ohnmacht U; Oakley G; Patel BKR; Yuen ESM; Benhadji KA; Rodon J
    Ann Oncol; 2018 Sep; 29(9):1911-1917. PubMed ID: 30060061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma.
    Borthakur G; Martinelli G; Raffoux E; Chevallier P; Chromik J; Lithio A; Smith CL; Yuen E; Oakley GJ; Benhadji KA; DeAngelo DJ
    Cancer; 2021 Feb; 127(3):372-380. PubMed ID: 33107983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.
    Even C; Lassen U; Merchan J; Le Tourneau C; Soria JC; Ferte C; Ricci F; Diener JT; Yuen E; Smith C; Oakley GJ; Benhadji KA; Massard C
    Invest New Drugs; 2020 Apr; 38(2):402-409. PubMed ID: 30953269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.
    Kondo S; Tajimi M; Funai T; Inoue K; Asou H; Ranka VK; Wacheck V; Doi T
    Invest New Drugs; 2020 Dec; 38(6):1836-1845. PubMed ID: 32578154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
    Bendell JC; Varghese AM; Hyman DM; Bauer TM; Pant S; Callies S; Lin J; Martinez R; Wickremsinhe E; Fink A; Wacheck V; Moore KN
    Clin Cancer Res; 2018 Jul; 24(14):3253-3262. PubMed ID: 29636360
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.
    Fujiwara Y; Tamura K; Kondo S; Tanabe Y; Iwasa S; Shimomura A; Kitano S; Ogasawara K; Turner PK; Mori J; Asou H; Chan EM; Yamamoto N
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):281-8. PubMed ID: 27312735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.
    Zauderer MG; Alley EW; Bendell J; Capelletto E; Bauer TM; Callies S; Szpurka AM; Kang S; Willard MD; Wacheck V; Varghese AM
    Invest New Drugs; 2021 Aug; 39(4):1081-1088. PubMed ID: 33660194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial.
    Patnaik A; Yap TA; Chung HC; de Miguel MJ; Bang YJ; Lin CC; Su WC; Italiano A; Chow KH; Szpurka AM; Yu D; Zhao Y; Carlsen M; Schmidt S; Vangerow B; Gandhi L; Xu X; Bendell J
    Clin Cancer Res; 2021 Mar; 27(5):1267-1277. PubMed ID: 33229456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study.
    Kim ES; Kelly K; Paz-Ares LG; Garrido P; Jalal S; Mahadevan D; Gutierrez M; Provencio M; Schaefer E; Shaheen M; Johnston EL; Turner PK; Kambhampati SRP; Beckmann R; Hossain A; John WJ; Goldman JW
    Clin Cancer Res; 2018 Nov; 24(22):5543-5551. PubMed ID: 30082474
    [No Abstract]   [Full Text] [Related]  

  • 15. A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.
    Besse B; Barlesi F; Demedts I; Fuentes Pradera J; Robinet G; Gazzah A; Soldatenkova V; Frimodt-Moller B; Kim JS; Vansteenkiste J
    Lung Cancer; 2019 Nov; 137():136-143. PubMed ID: 31586771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
    Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
    Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the effects of an oral notch inhibitor, crenigacestat (LY3039478), on QT interval, and bioavailability studies conducted in healthy subjects.
    Yuen E; Posada M; Smith C; Thorn K; Greenwood D; Burgess M; A Benhadji K; Ortega D; Chinchen L; Suico J
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):483-492. PubMed ID: 30539232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial.
    Chiorean EG; Picozzi V; Li CP; Peeters M; Maurel J; Singh J; Golan T; Blanc JF; Chapman SC; Hussain AM; Johnston EL; Hochster HS
    Cancer Med; 2023 Oct; 12(20):20353-20364. PubMed ID: 37840530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors.
    Wang F; Molina J; Satele D; Yin J; Lim VS; Adjei AA
    Invest New Drugs; 2019 Aug; 37(4):658-665. PubMed ID: 30382439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.